BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 1999

View Archived Issues

Priority review status granted to Immunex's MS drug

Read More

Abgenix files IND for ABX-EGF

Read More

Use of zonisamide for neurodegenerative disorders

Read More

Modulators of cGMP production developed at HMR

Read More

Klinge continues to focus on cytostatic/immunosuppressive carboxamides

Read More

Amgen reveals latest in inhibitors of matrix metalloproteinases

Read More

Novel paclitaxel analogues under evaluation at Bristol-Myers

Read More

Collaborative research at HMR and Genentech yields new vitronectin receptor antagonists

Read More

Antiherpesvirus agents in the Pharmacia & Upjohn pipeline

Read More

Spironolactone-containing drug regimen: the new gold standard for treating heart failure

Read More

Novalon and Ares-Serono enter research collaboration

Read More

Novartis exercises option to license complement inhibitor from Avant

Read More

Progen updates drug development programs

Read More

Janssen will copromote Pharmacia & Upjohn's new antidepressant in U.S.

Read More

First report of in vivo efficacy of nonthiazolidinedione PPAR-gamma activator

Read More

Z-350, a novel treatment for BPH with a dual mechanism of action

Read More

Licensing opportunity from NIH: novel and potent antiangiogenic molecule

Read More

American Home Products receives approvable letter for GERD therapy

Read More

Conformationally constrained putative atypical antipsychotics designed by European group

Read More

Structure and physicochemical properties of Metastat published

Read More

Wampole launches rapid diagnostic test for Lyme disease

Read More

Phase II trial results in colorectal and lung cancers support efficacy and tolerability of S-1

Read More

EntreMed signs manufacturing agreement for Angiostatin in preparation for phase I trials

Read More

CRP inhibition as a potential new target for lipid-lowering drugs

Read More

Archaeosomes with or without coenzyme Q10: biodistribution in mice after i.v., i.p. and p.o. dosing

Read More

Targeted doxorubicin chemotherapy for liver cancer tested in phase I trial

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing